Proof of concept: Exposing the myth of urethral atrophy after artificial urinary sphincter via assessment of circumferential recovery after capsulotomy and intraoperative pressure profiling of the pressure regulating balloon
Abstract:PurposeRate of continence after artificial urinary sphincter (AUS) placement appears to decline with time. After appropriate workup to exclude inadvertent device deactivation, development of urge or overflow incontinence, and fluid loss, many assume recurrent stress urinary incontinence (rSUI) to be secondary to nonmechanical failure, asserting urethral atrophy as the etiology. We aimed to characterize the extent of circumferential urethral recovery following capsulotomy and that of pressure regulating balloon… Show more
“…In humans with AUS devices, a fibrous capsule consistently forms not only around the AUS device, but also around the urethra that is within the region of the AUS cuff, even in patients without any clinical signs 10 . It was initially thought that urethral atrophy secondary to cuff placement around the urethra was responsible for humans with AUS developing stranguria, but it has now been determined that affected patients had compression of the urethra from the capsule associated with the AUS device 10,11 . In these studies, after capsulotomy or capsulectomy, the urethra returned to its normal shape from the “hour glass” appearance caused by capsular contracture 10,11 …”
Section: Discussionmentioning
confidence: 99%
“…10 It was initially thought that urethral atrophy secondary to cuff placement around the urethra was responsible for humans with AUS developing stranguria, but it has now been determined that affected patients had compression of the urethra from the capsule associated with the AUS device. 10,11 In these studies, after capsulotomy or capsulectomy, the urethra returned to its T A B L E 1 Bacteria cultured from AUS device and associated capsule, fluid associated with the AUS device and capsule or both…”
Background
Urethral obstruction secondary to artificial urethral sphincter (AUS) implantation is a recognized complication in dogs. However, urethral obstruction secondary to AUS‐associated capsule formation has been described rarely.
Hypothesis
Describe clinical and diagnostic findings, management, and outcome in 6 dogs with urethral obstruction secondary to AUS‐associated capsule formation.
Animals
Six client‐owned dogs.
Methods
Retrospective study. Medical records between January 1, 2010, and June 30, 2021, were reviewed to identify dogs with urethral obstruction associated with the AUS device.
Results
The AUS device was implanted a median of 884 days (range, 20‐2457 days) before presentation for urethral obstruction. Median age at time of urethral obstruction was 4.7 years (range, 3.1‐8.7 years). Clinical signs at the time of urethral obstruction were stranguria (n = 4), pollakiuria (3), weak urine stream (2), and worsened urinary incontinence (1). In all dogs, the urethra was noted to be stenotic during urethroscopy and positive contrast cystourethrography. All dogs underwent surgery, and a fibrous capsule associated with the AUS was found to be causing urethral stenosis. Resolution of urethral obstruction occurred in all dogs after transection or removal of the capsule. Positive bacterial cultures were obtained from the capsule, AUS, or both in all dogs. Recurrence of urethral obstruction had not occurred in any dog at the time of follow‐up.
Conclusions and Clinical Importance
Urethral obstruction secondary to capsule formation is an uncommon but clinically important complication associated with use of the AUS. Continued investigation is needed to evaluate this complication more thoroughly, and its possible association with infection.
“…In humans with AUS devices, a fibrous capsule consistently forms not only around the AUS device, but also around the urethra that is within the region of the AUS cuff, even in patients without any clinical signs 10 . It was initially thought that urethral atrophy secondary to cuff placement around the urethra was responsible for humans with AUS developing stranguria, but it has now been determined that affected patients had compression of the urethra from the capsule associated with the AUS device 10,11 . In these studies, after capsulotomy or capsulectomy, the urethra returned to its normal shape from the “hour glass” appearance caused by capsular contracture 10,11 …”
Section: Discussionmentioning
confidence: 99%
“…10 It was initially thought that urethral atrophy secondary to cuff placement around the urethra was responsible for humans with AUS developing stranguria, but it has now been determined that affected patients had compression of the urethra from the capsule associated with the AUS device. 10,11 In these studies, after capsulotomy or capsulectomy, the urethra returned to its T A B L E 1 Bacteria cultured from AUS device and associated capsule, fluid associated with the AUS device and capsule or both…”
Background
Urethral obstruction secondary to artificial urethral sphincter (AUS) implantation is a recognized complication in dogs. However, urethral obstruction secondary to AUS‐associated capsule formation has been described rarely.
Hypothesis
Describe clinical and diagnostic findings, management, and outcome in 6 dogs with urethral obstruction secondary to AUS‐associated capsule formation.
Animals
Six client‐owned dogs.
Methods
Retrospective study. Medical records between January 1, 2010, and June 30, 2021, were reviewed to identify dogs with urethral obstruction associated with the AUS device.
Results
The AUS device was implanted a median of 884 days (range, 20‐2457 days) before presentation for urethral obstruction. Median age at time of urethral obstruction was 4.7 years (range, 3.1‐8.7 years). Clinical signs at the time of urethral obstruction were stranguria (n = 4), pollakiuria (3), weak urine stream (2), and worsened urinary incontinence (1). In all dogs, the urethra was noted to be stenotic during urethroscopy and positive contrast cystourethrography. All dogs underwent surgery, and a fibrous capsule associated with the AUS was found to be causing urethral stenosis. Resolution of urethral obstruction occurred in all dogs after transection or removal of the capsule. Positive bacterial cultures were obtained from the capsule, AUS, or both in all dogs. Recurrence of urethral obstruction had not occurred in any dog at the time of follow‐up.
Conclusions and Clinical Importance
Urethral obstruction secondary to capsule formation is an uncommon but clinically important complication associated with use of the AUS. Continued investigation is needed to evaluate this complication more thoroughly, and its possible association with infection.
“…Capsule incision is increasingly cited as a potential treatment for recurrent incontinence. Dr Terlecki’s retrospective analysis of 7 patients published in Investigative and Clinical Urology as a proof-of-concept article is often cited 1 ; however, we feel that this paper demonstrates the multifaceted nature of recurrent incontinence more so than the efficacy of capsulotomy alone. Notably in their study, 6 of the 7 patients had balloon pressures less than 61 cm H 2 O at the time of revision.…”
mentioning
confidence: 83%
“…Additionally, they performed a full component replacement in all with replacement cuffs ranging in sizes from smaller to larger than the original and only a short mention of number of subsequent pad usage for clinical follow-up. 1 While the argument is made that the urethra diameter increased more than a centimeter after incision, we do not think this relates at all to clinical outcomes. Size of the urethra in primary placement cases has never been thought to relate to better or worse outcomes for continence in the literature, but rather cuff downsizing and appropriate cuff sizing has proven to be an effective management of recurrent incontinence, with appropriate sizing reducing need for repeated revision.…”
“…In artificial urinary sphincter (AUS) revision cases such as those described in this manuscript (ie, non-eroded, functional devices, with worsening objective and subjective incontinence), 1 I have implemented the technique of capsule incision at the time of in situ AUS replacement and will now routinely incise the capsule bilaterally, and laterally, to allow for “expansion” of the sponge prior to replacement. 2 The pre-/post-incision measurement differences are generally 1 cm, and I have been amazed at how much the urethra appears to “recover” after these incisions. Though “wasting” is initially present, once the capsule is incised, it is clear that the urethra is not atrophic, as has been shown by others.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.